Holen Sie sich die Stockscreener-App
130.34
0.05%
0.06
Handel nachbörslich:
130.50
0.16
+0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
How Gilead Is Working With Cultural Influencers to Bring Attention to HIV Stigma and Elevate HIV Prevention - IMDb
Gilead, Merck weekly HIV pill maintains suppression in Phase III switch studies - The Pharma Letter
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating - The Motley Fool
Why Is Gilead Sciences (NASDAQ:GILD) Trending on the Nasdaq? - Kalkine Media
[AIDS 2026] [Press release] Gilead & Meck: Investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV who switched antiretroviral therapy - European AIDS Treatment Group
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026 - Yahoo! Finance Canada
Gilead Sciences to release Q2 2026 results on August 4 - scanx.trade
Gilead Sciences stock trades steady as HIV and oncology pipeline supports long term growth - Ad-hoc-news.de
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials - Reuters
ETFs Investing in Gilead Sciences, Inc. Stocks - TradingView
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Press Release: Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Moomoo
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Business Wire
Gilead and Merck report weekly HIV trial results - grafa.com
GILD Downgraded by Leerink Partners -- Price Target Lowered to $127 - GuruFocus
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Benzinga
Preferred dividends of Gilead Sciences, Inc. – BCS:GILDCL1 - TradingView
Gilead to present HIV prevention and treatment data at AIDS 2026 - Investing.com Canada
Gilead, Merck’s phase 3 data back first weekly HIV pill - Fierce Pharma
Gilead Sciences' Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More - 24/7 Wall St.
Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike… - marketscreener.com
Gilead Sciences stock trades steady as HIV and oncology pipeline supports outlook - Ad-hoc-news.de
Lobbying Update: $1,590,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Benzinga
Gilead Sciences (GILD) Downgraded by Leerink Partners Amid Marke - GuruFocus
Car T Cell Therapy Market Set to Booming Growth 2026-2033 | Novartis AG, Gilead Sciences, Inc - EIN News
Gilead Sciences stock trades steady as HIV and oncology pipeline underpins recent earnings - Ad-hoc-news.de
Gilead Sciences stock trades steady as HIV and oncology portfolio supports earnings trajectory - ad-hoc-news.de
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MSN
Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market Appreciates - Seeking Alpha
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Gilead Built Its Foundation On HIV; Is It Now In Trouble? - Investor's Business Daily
With Up To Date campaign, Gilead brings HIV prevention into the dating conversation - Medical Marketing and Media
Gilead Sciences synthesizes new KRAS mutant inhibitors - BioWorld News
Gilead Sciences chief comm & corp aff officer sells $389,757 in stock By Investing.com - Investing.com South Africa
Gilead Sciences stock trades steadily as oncology progress and HIV franchise support valuation - ad-hoc-news.de
Form 4 Gilead Sciences Inc For: 16 July By Investing.com - Investing.com Nigeria
Gilead Sciences CFO Andrew Dickinson sells $389,776 in stock By Investing.com - Investing.com South Africa
Insider Sell: Johanna Mercier Sells Shares of Gilead Sciences In - GuruFocus
Gilead Sciences CFO Andrew Dickinson sells $389,776 in stock - Investing.com
Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan - Stock Titan
Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overv - GuruFocus
Gilead Sciences chief comm & corp aff officer sells $389,757 in stock - Investing.com
Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Harrison Ford Among Speakers at 2026 Social Impact Summit - The Hollywood Reporter
Sepideh Moafi, Harrison Ford, Niecy Nash-Betts, Laverne Cox Added to 2026 Social Impact Summit, Hosted by The Hollywood Reporter and Social Impact Fund - Yahoo
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Form 144 GILEAD SCIENCES For: 15 July By Investing.com - Investing.com Canada
Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier - Stock Titan
GILD (NASDAQ: GILD) holder plans 3,000-share common stock sale - Stock Titan
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity? - 24/7 Wall St.
Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo - MSN
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1 - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Quest Diagnostics (DGX) and Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences (GILD) AGM 2026 Summary - Quartr
Gilead Sciences, Inc. (GILD) Stock Analysis: Promising 21.93% Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong. - Yahoo Finance
0.48%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):